Similarly, the oral and selective BTK inhibitor PCI-32765 (ibrutinib) inhibits MM cell growth and MM cell-induced osteolysis of implanted human bone chips in severe combined immunodeficient (SCID) mice [13]. This evidence concerns the gene BTK and Miyoshi myopathy.